The quarter landed above the standing earnings bar. Normalized FFO was $0.54 per diluted share versus $0.42 a year earlier, while the published full-year consensus was roughly $2.01 per share; the company now guides to $2.15-$2.19, above both that reference point and its prior $2.03-$2.09 range. The filing does not provide a reliable quarter-specific NFFO consensus, so the full-year comparison is the cleaner expectation anchor. (NAREIT FFO/NFFO Reconciliation; 2026 Guidance)
| Metric | Q2 2025 | Q2 2026 | Change / expectation |
|---|---|---|---|
| Normalized FFO per diluted share | $0.42 | $0.54 | +28.6% (NAREIT FFO/NFFO Reconciliation) |
| NAREIT FFO per diluted share | $0.41 | $0.51 | +24.4% (Earnings Metrics) |
| Total same-store NOI | $99.2 million | $112.3 million | +13.2% (Same-Store NOI Performance) |
| FY 2026 NFFO guidance per share | — | $2.15-$2.19 | Above published consensus of roughly $2.01 |
| FY 2026 total same-store NOI guidance | — | 11%-13% | Raised from the prior 9%-12% range |
The real operating upside is concentrated in senior housing, not spread evenly across the portfolio. Same-store NOI rose 16.1% at integrated senior health campuses and 20.5% at senior housing operating properties, helped by higher occupancy and stronger pricing. ISHC same-store occupancy reached 90.7%, up 180 basis points, while SHOP occupancy reached 88.7%, up 278 basis points; SHOP’s margin expanded 242 basis points to 22.3%. (Same-Store NOI Performance — ISHC; Same-Store NOI Performance — SHOP)
The quarter also shows why the guidance increase is credible. The company raised segment growth targets to 13%-16% for ISHC and 18%-21% for SHOP, and expects to fund $150-$170 million of development spending while assuming no additional acquisitions beyond approximately $1.4 billion already closed year to date. That points to internally visible growth from occupancy recovery, operating leverage and recently acquired assets rather than relying on another acquisition wave. (2026 Guidance)
Outpatient medical remains the clear drag. Its same-store NOI increased only 1.7%, while occupancy fell 87 basis points to 92.6% and the margin contracted 59 basis points to 62.7%; trailing twelve-month retention was only 65.2%. This offsets part of the senior-housing strength, but OM contributes just 12.8% of annualized portfolio cash NOI versus 81.2% combined for ISHC and SHOP. (Portfolio Overview; Same-Store NOI Performance — Outpatient Medical; OM Absorption)
Balance-sheet risk is manageable but the 2027 refinancing point matters. Net debt stood at 2.5 times annualized adjusted EBITDA, with interest coverage of 7.1 times and fixed-charge coverage of 5.5 times. However, $550 million, or 42.1% of total debt, matures in 2027, and the two swaps supporting that term loan mature on January 19, 2027. That is not an immediate earnings miss, but it is the main constraint on how much of the operating improvement ultimately reaches equity holders. (Adjusted EBITDA, Coverage Ratios & Net Debt Reconciliation; Debt Maturities and Principal Payments)
Net read: a genuine positive surprise, led by senior housing and reinforced by higher guidance. The result is more than a larger portfolio producing larger absolute numbers: same-store margins, occupancy and full-year targets all improved. The weak outpatient trends and upcoming 2027 refinancing prevent this from being uniformly strong, but the filing shifts the central expectation toward faster organic growth than the market had been carrying.
Read the original 8-K on SEC EDGAR ↗